AGIO Stock Chart & Stats
$1222.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1222.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1,222.00 - $1,224.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$41.97B
Enterprise Value$1.62B
Total Cash (Recent Filing)$617.58M
Total Debt (Recent Filing)$31.17M
Price to Earnings (P/E)―
Beta-0.09
Next Earnings
Nov 05, 2026EPS Estimate
-23.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.01
Shares Outstanding59,701,880
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.32
Price to Sales (P/S)29.21
P/FCF Ratio-4.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$853.47Price Target Upside-30.16% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-108.84
Revenue Forecast (FY)$3.34B
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginStrong revenue growth paired with an approximately 82% gross margin indicates meaningful product economics and increasing commercial traction. If growth continues, the combination can provide operating leverage over time, support reinvestment in the pipeline, and strengthen the foundation for eventual profitability.
Strong Balance SheetLow leverage and substantial liquidity give Agios financial flexibility to fund commercialization and clinical development without relying heavily on near-term borrowing. This capital base can help sustain investment through development cycles while reducing balance-sheet pressure as the company scales.
Commercial And Pipeline ExpansionPrescription growth, broad payer coverage, and advancement of multiple pipeline programs create several avenues for durable expansion beyond the existing revenue base. Progress across commercial and clinical assets can diversify future growth and improve the strategic value of Agios's hematology-focused platform.
Bears Say
Persistent Cash BurnLarge operating and free-cash-flow deficits show that the current business is not yet self-funding despite commercial progress. Continued cash consumption may require sustained use of reserves or future financing, limiting financial flexibility if profitability and operating leverage do not improve.
Deep Operating Losses And High SpendingSubstantial losses and elevated research, development, and commercial expenses indicate that revenue has not yet reached a level capable of supporting the operating structure. This weak earnings profile can persist while programs advance, making the path to sustainable profitability dependent on significant execution and revenue growth.
Revenue Variability And Rebate PressureOne-time stocking benefits and order timing can make reported revenue uneven, complicating assessment of underlying demand and operating leverage. Expected gross-to-net deductions, including higher Medicaid rebates in sickle cell, may also reduce realized revenue and constrain the economics of future indication expansion.
Agios Pharma News
AGIO FAQ
What was Agios Pharma’s price range in the past 12 months?
Agios Pharma lowest stock price was $1222.00 and its highest was $1224.00 in the past 12 months.
What is Agios Pharma’s market cap?
Agios Pharma’s market cap is $41.97B.
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s upcoming earnings report date is Nov 05, 2026 which is in 5 days.
How were Agios Pharma’s earnings last quarter?
Agios Pharma released its earnings results on Jul 30, 2026. The company reported -$31.75 earnings per share for the quarter, missing the consensus estimate of -$31.092 by -$0.658.
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Overvalued.
Does Agios Pharma pay dividends?
Agios Pharma does not currently pay dividends.
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate is -23.37.
How many shares outstanding does Agios Pharma have?
Agios Pharma has 59,701,880 shares outstanding.
What happened to Agios Pharma’s price movement after its last earnings report?
Agios Pharma reported an EPS of -$31.75 in its last earnings report, missing expectations of -$31.092. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Agios Pharma?
Currently, no hedge funds are holding shares in MX:AGIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agios Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$853.47 (-30.16% Downside)
$853.47 (-30.16% Downside)
Blogger Sentiment
Bullish
MX:AGIO Sentiment 100%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-11.27%
12-Months-Change
Fundamentals
Return on Equity
-35.67%
Trailing 12-Months
Asset Growth
-24.66%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Agios Pharma
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
AGIO Company Deck
AGIO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated substantial commercial momentum (AQVESME launch traction and U.S.-centric revenue), a meaningful near-term regulatory catalyst (Mitapivat PDUFA on Nov 1), and active pipeline expansion (cevidoplenib, AG-236, AG-181), supported by a strong cash position (~$1B). Offsetting these positives are elevated R&D and SG&A spending, a sizable net loss ($100.7M), quarter-to-quarter revenue variability (including a one-time $5M stocking benefit in Q2), and potential pricing/net revenue pressures for a sickle cell indication due to higher Medicaid mix and rebates. On balance, the operational and pipeline progress and the regulatory catalyst outweigh the financial and visibility challenges.View all MX:AGIO earnings summariesAGIO Stock 12 Month Forecast
Average Price Target
$853.47
▼(-30.16% Downside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Iovance Biotherapeutics
―
Intellia Therapeutics
―
Beam Therapeutics
―
Nurix Therapeutics
―